• Explore /
  • Poster
  • / A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.

A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.

Abstract Poster

Authors

null

Nathan Hale Fowler

The University of Texas MD Anderson Cancer Center, Houston, TX

Nathan Hale Fowler , Wolfgang Hiddemann , John Leonard , Julie S. Larsen , Esther Rose , Sen Hong Zhuang , Jessica Vermeulen , Steven Sun , Lisa Mentzer , Tzu-Min Yeh , Gilles A. Salles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT01974440

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS8601)

DOI

10.1200/jco.2015.33.15_suppl.tps8601

Abstract #

TPS8601

Poster Bd #

419a

Abstract Disclosures

Similar Posters

First Author: Nathan Hale Fowler

First Author: Laurie Helen Sehn

First Author: Jason Westin

First Author: Laurie Helen Sehn